H.R. 3174: Made in America Manufacturing Finance Act

A bipartisan House bill, the Made in America Manufacturing Finance Act, would sharply raise how much small manufacturers can borrow through government-backed SBA programs. It narrows eligibility to firms whose plants are fully located in the U.S., making the loan cap hike an explicit test of how far Washington will go to subsidize domestic production.

The bill rewrites the Small Business Act’s definition of a "small manufacturer" to cover only firms in manufacturing NAICS codes whose production facilities are all in the U.S., locking in an onshoring test for access to the higher caps. Supporters pitch it as a way to unleash pent-up investment for equipment, factory expansions and working capital, and SBA leadership has already cheered House passage as a pro-growth move. But cheaper credit does not solve chronic bottlenecks in permitting, power access and workforce training — meaning companies may borrow more without actually getting new plants built on time or on budget.

The change would most directly benefit a narrow slice of firms that are capital-intensive enough to need larger loans but still small enough to qualify as "small" under SBA rules. Banks and nonbank lenders that originate SBA loans would gain a richer pipeline of high-dollar deals with government guarantees, even as rising defaults in other corners of small-business lending raise questions about who ultimately eats the losses. With no new guardrails on how lenders underwrite or structure these larger loans, critics worry the government is quietly socializing more risk just as interest costs and input prices remain volatile.

The bill is framed as a re-industrialization tool, but it is really a test of how much Washington wants to lean on finance, rather than industrial policy, to deliver on "Made in America" promises. If the higher caps mostly fund acquisitions, refinancing or incremental upgrades at existing plants, the measure could entrench current players rather than jump-start new production nodes. If they instead underwrite greenfield projects in key supply chains — batteries, semiconductors, medical gear — the headline could shift from subsidized leverage to accelerated reshoring. The stakes are whether this becomes a quiet credit expansion or a visible shift in where things are actually made.